Meadowbrook Wealth Management LLC raised its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 110.8% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 3,268 shares of the company’s stock after acquiring an additional 1,718 shares during the period. Eli Lilly and Company comprises 4.2% of Meadowbrook Wealth Management LLC’s portfolio, making the stock its 6th biggest position. Meadowbrook Wealth Management LLC’s holdings in Eli Lilly and Company were worth $3,920,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of LLY. RDA Financial Network grew its stake in shares of Eli Lilly and Company by 40.2% during the 2nd quarter. RDA Financial Network now owns 4,517 shares of the company’s stock worth $5,418,000 after acquiring an additional 1,295 shares in the last quarter. Dogwood Wealth Management LLC lifted its position in Eli Lilly and Company by 49.5% during the 2nd quarter. Dogwood Wealth Management LLC now owns 746 shares of the company’s stock worth $895,000 after buying an additional 247 shares in the last quarter. Boltwood Capital Management grew its holdings in shares of Eli Lilly and Company by 1.0% in the 2nd quarter. Boltwood Capital Management now owns 1,878 shares of the company’s stock valued at $2,253,000 after acquiring an additional 18 shares in the last quarter. Trilogy Capital Inc. grew its holdings in shares of Eli Lilly and Company by 9.5% in the 2nd quarter. Trilogy Capital Inc. now owns 5,952 shares of the company’s stock valued at $7,139,000 after acquiring an additional 516 shares in the last quarter. Finally, Box Hill Private Wealth LLC increased its position in shares of Eli Lilly and Company by 3.4% in the second quarter. Box Hill Private Wealth LLC now owns 520 shares of the company’s stock valued at $624,000 after acquiring an additional 17 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.
More Eli Lilly and Company News
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Lilly plans to provide limited early access to experimental obesity drug retatrutide before potential U.S. FDA approval. The next-generation therapy could strengthen Lilly’s leadership in the rapidly expanding obesity market, although early access does not guarantee regulatory approval. Eli Lilly to offer early access to next-gen obesity drug to some patients
- Positive Sentiment: The FDA granted Breakthrough Therapy designation to olomorasib for previously treated patients with advanced pancreatic cancer carrying KRAS G12C mutations. The designation may accelerate development and regulatory review of Lilly’s investigational cancer treatment, expanding its pipeline beyond diabetes and obesity. Lilly’s olomorasib receives FDA Breakthrough Therapy designation
- Positive Sentiment: Investor attention remains focused on strong demand for Mounjaro and Zepbound, which are expected to drive second-quarter revenue and earnings growth. Lilly’s recent results showed rapid year-over-year expansion, while several analysts maintain price targets above current trading levels. Will Mounjaro and Zepbound Drive Lilly’s Q2 Results
- Neutral Sentiment: LLY is approaching a major earnings catalyst. Market commentary points to potential upside if sales exceed expectations but also warns that the stock could experience a large move in either direction because strong growth expectations are already embedded in its valuation. Eli Lilly Could Swing Over $76 Billion in Value After Earnings
- Negative Sentiment: Valuation analyses suggest the stock may be priced above estimates of its cash-flow-based intrinsic value after rising more than 300% over five years. This raises the bar for earnings, guidance and future obesity-drug growth. Eli Lilly Stock Looks Below Fair Value on Cash Flow
- Negative Sentiment: Novo Nordisk is attempting to regain momentum in the obesity-drug race, potentially increasing pricing and market-share pressure on Lilly. Separately, an executive’s recent open-market sale provides a modest negative sentiment signal, though it does not establish a change in company fundamentals. Obesity battle heats up as Novo competes with Lilly
Analyst Ratings Changes
View Our Latest Stock Report on LLY
Eli Lilly and Company Trading Down 2.3%
Shares of NYSE:LLY opened at $1,122.32 on Tuesday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,249.45. The stock has a market cap of $1.06 trillion, a PE ratio of 39.87, a P/E/G ratio of 1.43 and a beta of 0.51. The business has a 50 day moving average of $1,153.77 and a 200-day moving average of $1,044.22. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.
Eli Lilly and Company Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s payout ratio is 24.58%.
About Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Read More
- Five stocks we like better than Eli Lilly and Company
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
